Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Lenalidomide in R/R Elderly Non-GCB DLBCL
NCT04796857Phase 2Unknown
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in diffuse large B-cell lymphoma (DLBCL). Primary endpoints: Overall Response Rate at 24 months and The optimal dosage of lenalidomide at 6 months. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04796857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796857.